The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 1: Their Similarities Are Different
Clinical Neuroscience Research Center in San Diego and the Department of Psychiatry at the University of California San Diego, USA. The Journal of Clinical Psychiatry
(Impact Factor: 5.5).
11/2000; 61(10):710-1. DOI: 10.4088/JCP.v61n1001
Three new cholinesterase inhibitors, donepezil, rivastigmine, and galantamine, all inhibit the enzyme AChE. Rivastigmine also inhibits BuChE, which could lead to additional benefits in late-stage Alzheimer's disease, but also cause more GI side effects at initiation of therapy. Galantamine is also an allosteric modulator of nicotinic receptors, which could lead to additional efficacy for attention and for behaviors mediated by neurotransmitters other than ACh. We are now entering an exciting era where the options for treating the devastating illness Alzheimer's disease are multiplying and creating a foundation upon which new therapies with new mechanisms of action can be built.
Available from: etd.ohiolink.edu
The Journal of Clinical Psychiatry 12/2000; 61(11):813-4. DOI:10.4088/JCP.v61n1101 · 5.50 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: The authors review the literature from the last year examining the benefits of cholinesterase inhibitors in the treatment of behavioral disturbance in Alzheimer's disease (AD) and other dementias. Previous review has indicated that cholinesterase inhibitors have psychotropic properties. We found more evidence to support both the benefits of cholinesterase inhibitors in behavioral disturbance, and that specific behaviors may be selectively responsive to treatment.
Current Psychiatry Reports 07/2001; 3(3):251-8. DOI:10.1007/s11920-001-0061-7 · 3.24 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.